Prof. Christophe Mariette unfortunately passed away in spring 2017. We thank him for his tremendous efforts for this trial.
Introduction
When this trial was designed in 2008/09, the multimodal treatment of locally advanced resectable adenocarcinoma and squamous cell carcinoma (SCC) of the esophagus consisted of conventional chemotherapy combined with radiotherapy and/or surgery. However, a plateau had been reached in terms of efficacy, with more than half of all patients still dying within 5 years due to tumor progression [1] . At that time, the therapeutic use of antagonists of growth factor signal transduction was an emerging possibility for several different tumor types. In 2006, Bonner et al. showed in a randomized trial that the addition of the antiepidermal growth factor receptor (EGFR) monoclonal, chimeric, IgG1 antibody cetuximab to radiotherapy in the treatment of stage III and IV loco-regionally advanced SCC of the head and neck improved local control and overall survival (OS) compared with radiotherapy alone [2] .
The Swiss Group for Clinical Cancer Research (SAKK) investigated a neoadjuvant schedule with two cycles of induction chemotherapy, including a platinum-based drug and a taxane, followed by chemoradiation for locally advanced esophageal carcinoma [3] . The feasibility and safety of the addition of cetuximab to this regimen was proved by the same group, showing a high pathological complete remission rate and no increase of relevant toxicity including postoperative mortality [4] . The good tolerability of EGFR-antibody as a single agent makes it a candidate for treating occult residual disease after surgery where chemotherapy and radiotherapy are usually not feasible due to postoperative morbidity and convalescence.
These results encouraged us to initiate a prospective, randomized phase III trial to test whether the addition of cetuximab to a multimodal treatment might improve the long-term prognosis of patients with locally advanced esophageal carcinoma.
Patients and methods

Patients
Previously untreated patients with histologically confirmed SCC (from 5 cm below the entrance of the esophagus into the thorax) or adenocarcinoma of the thoracic esophagus, including the gastro-esophageal junction AEG types I and II according to Siewert were included. Tumors had to be locally advanced, but resectable (stage T 2 N 1-3 , T 3 N any , or T 4a N any , if technically resectable with curative intent). Eligible patients were aged 18-75 years, with a WHO performance status of 1, with adequate hematologic, renal and hepatic function and a normal lung function. Patients with metastases (including cervical or celiac lymph node involvement [M1a]), concurrent cancer, uncontrolled significant comorbidity, or infiltration of the tracheo-bronchial tree were not eligible.
Study design
This randomized, open-label phase III trial (ClinicalTrials.gov identifier NCT01107639) was carried out according to the declaration of Helsinki and Good Clinical Practice guidelines. The protocol was approved by the ethics committee of each center and all patients gave written informed consent.
Pretreatment staging comprised upper endoscopy with biopsy, positron emission tomography-computed tomography scan, endoscopic ultrasound, and bronchoscopy in case of tumors at or above the tracheal bifurcation. Any uncertainties of staging were discussed by the multidisciplinary team before treatment, including further investigations and final decision about eligibility.
Patients were randomly assigned (1 : 1) to receive multimodal therapy (control) with or without neoadjuvant and adjuvant cetuximab. Randomization was centralized at the SAKK Coordinating Center with stratification by center, histological type (i.e. adenocarcinoma or SCC), stage (T2 versus T3/4), and gender using the minimization method with 90% allocating probability.
In the control arm, preoperative treatment consisted of two cycles of induction chemotherapy followed by chemoradiation. Induction chemotherapy consisted of cisplatin 75 mg/m 2 and docetaxel (Taxotere V R , Aventis Pharma AG, Switzerland) 75 mg/m 2 administered intravenously (IV) on days 1 and 22. Chemoradiation started 3 weeks after the second induction chemotherapy cycle. Three-dimensional (3D) conformal radiotherapy of 45 Gy (25 fractions of 1.8 Gy) was given over 5 weeks with 6-18 MV photons. Intensity-modulated radiation therapy, volumetric modulated arc therapy, and tomotherapy were allowed. The planning target volume included all known areas of disease with a 5 cm cranial and caudal margin and a 2 cm circumferential margin. The dose to the organs at risk was predefined, and quality assurance program for radiotherapy was in place. Concomitant chemotherapy consisted of IV cisplatin 25 mg/m 2 and docetaxel 20 mg/m 2 administered weekly for 5 weeks on an outpatient basis. Surgery was scheduled 3-8 weeks after the completion of chemoradiation.
In the cetuximab group, the same neoadjuvant chemo-and radiotherapy schedule was applied, with the addition of cetuximab 250 mg/m 2 (Erbitux V R , Merck KGaA, Germany) administered weekly throughout induction chemotherapy (six times) and chemoradiation (five times), with an initial loading dose on day 1 of 400 mg/m 2 . Postoperative cetuximab therapy (500 mg/m 2 fortnightly for 3 months) started within 3-6 weeks after surgery.
En bloc R0 resection was carried out (by definition, radical resection refers to the primary tumor and to lymphatic drainage areas). Minimal invasive surgery was accepted as part of the procedure.
An esophageal en bloc resection had to be done by abdomino-thoracal or thoraco-abdomino-cervical approach for SCC. A complete two-field lymphadenectomy was mandatory. The anastomosis was carried out either in the apex of the right chest or in the left neck by prevertebral or retrosternal transposition. Routine reconstruction was done by a gastric tube according to the technique of Akiyama.
For adenocarcinoma of the esophageal junction (Siewert type I), a subtotal esophagectomy was the preferred operation. For adenocarcinoma of the gastro-esophageal junction (Siewert type II), a transhiatal partial esophagectomy, including total gastrectomy with adequate lymphadenectomy and transhiatal esophago-jejunal anastomosis was performed.
The patients were closely monitored for toxic effects according to CTCAE v4.0. In case of tumor-or treatment-induced dysphagia early insertion of a feeding tube was recommended. In cases of grade 4 esophagitis, chemoradiation was interrupted until toxicity resolved to grade 3. Cisplatin was replaced by carboplatin if grade 3 nephrotoxicity occurred. In case of R1/2 resection, it was up to the local investigator to define possible further local therapy.
Oncological follow-up was carried out clinically and radiologically every 3 months following surgery or after the end of neoadjuvant treatment of the first 3 years and then half-yearly until 5 years postoperatively.
End points
The primary end point of this trial was progression-free survival (PFS) defined as time from randomization to tumor progression, recurrence after surgery, or death from any cause, whichever came first. Inoperability or nonradical resection was only an event if it was caused by progressive tumor. Secondary outcomes were OS, histologic remission, R0-resection rate, and in-hospital mortality. Additionally, in patients reaching a complete resection the time to loco-regional failure and time to distant failure were calculated from date of surgery to date of first documented loco-regional or distant failure, or death due to tumor. Histologic remission was assessed according to the tumor regression model of Mandard [5] . In-hospital mortality included any death (therapy, cancer, or other related cause) occurring after surgery while the patient remained in hospital.
Statistical analysis
To detect an increase in PFS rate at 3 years from 38% (control) to 53% (cetuximab) [hazard ratio (HR) 0.656) with 80% power and two-sided 5% significance level, 180 events were required allowing for one interim efficacy analysis after 20% of the events had occurred. The total sample size was 300 patients (150 per treatment arm).
An independent data monitoring committee (IDMC) reviewed yearly safety reports and the results of the interim efficacy analysis.
All efficacy analyses were based on the intention-to-treat (ITT) population, defined as all randomized, eligible patients who received at least one dose of trial therapy. All safety analyses were based on the safety population, defined as all randomized patients who received at least one dose of trial therapy.
For all time-to-event end points, the medians and corresponding confidence intervals (CIs) were estimated using the Kaplan-Meier method and compared between treatment arms using log-rank tests. HRs were estimated using Cox regression models. Subgroup analyses were carried out for predefined variables. Two-tailed tests with significance level 0.05 were used for all analyses. As no adjustment for multiple testing was applied for analyses other than the primary end point analysis, they were considered to be exploratory and hypothesis generating.
Due to a slowing event rate that reached a plateau, the IDMC decided to perform the primary analysis in December 2016, despite the fact that only 166 PFS events had occurred (instead of the planned 180).
Results
Patient disposition
In total, 300 patients were randomly assigned to receive cetuximab (n ¼ 149) or control (n ¼ 151) at 53 centers in four European countries between May 2010 and December 2013. Three patients were recognized to have metastatic disease after treatment had already started (Figure 1 ). These patients were included in the safety analyses, but excluded from the ITT efficacy analysis. The median age of all enrolled patients was 61 years, 263 (88%) of 300 patients were men, 246 (82%) had uT3 disease, and 269 (90%) were node-positive. Baseline characteristics were generally well balanced between the two groups ( Table 1) .
Compliance
Overall, 143 of 149 patients (96%) in the cetuximab group and 146 of 151 patients (97%) in the control group completed both induction chemotherapy cycles; with 140 of 149 patients (94%) and 145 of 151 patients (96%) starting chemoradiation in the respective groups (Figure 1) . The centrally performed quality assurance of radiotherapy showed only two major deviations, one in each arm.
Median time from the last administration of radiotherapy to surgery was 6 weeks in both groups and overall a similar proportion of patients underwent surgical resection in the cetuximab and control groups (89% versus 86%, respectively), but more patients in the control group did not undergo surgical resection (13 versus 6 patients) due to poor condition, extent of disease or progressive disease. Median ICU stay was 4 days in both groups. In total, 100 of 131 resected patients (76%) in the cetuximab group started, and 80 of them (80%) completed adjuvant cetuximab therapy.
Surgery and pathological remission rate
Three quarters of all resections were done by a transthoracic approach, 79% in the cetuximab group, 70% in the control group; the others by a transmediastinal approach. The median numbers of resected lymph nodes were 19 and 18 for cetuximab and control groups, respectively. The anastomosis was located cervical in one-third of all cases, and thoracal in two-thirds, with no difference between the two treatment arms. The R0 resection rate was 95% in the cetuximab group and 97% for controls. A complete pathologic remission (pT0, TRG 1 according to the Mandard classification) was reached in 37% of patients in the cetuximab group and 33% of controls (adenocarcinoma: 29% versus 26%; SCC: 51% versus 48%, respectively).
Efficacy
Median follow-up time for all patients was 4.0 years. Median PFS was 2.9 years (95% CI, 2.0 to not reached) and 2.0 years (95% CI, 1.5-2.8) for the cetuximab and control groups, respectively (HR 0.79; 95% CI, 0.58-1.07, P ¼ 0.13; Figure 2 ). In total, 76 patients (51%) in the cetuximab group and 90 (60%) of controls experienced an event. The respective PFS rates at 1, 2, 3, and 4 years were 74%, 58%, 50%, and 48% in arm A and 73%, 50%, 41%, and 37% in arm B.
Median OS in the cetuximab group was 5.1 years (95% CI, 3.7 to not reached) and 3.0 years (95% CI, 2.2-4.2) in the control group (HR 0.73; 95% CI, 0.52-1.01, P ¼ 0.055; Figure 2 ). The respective OS rates at 1, 2, 3, and 4 years were 85%, 71%, 62%, and 56% in arm A and 79%, 63%, 51%, and 43% in arm B.
Overall, 58 patients suffered from loco-regional failure after R0-resection (21 in the cetuximab group and 37 controls). The time to loco-regional (in-radiotherapy field) failure was significantly longer in the cetuximab arm (median not reached, HR 0.53; 95% CI, 0.31-0.90, P ¼ 0.017; Figure 2 ). The respective loco-regional failure-free rates at 1, 2, 3, and 4 years were 88%, 85%, 79%, and 79% in arm A, as compared with 86%, 71%, 63%, and 61% in arm B. In contrast, we observed no difference in the time to distant failure between treatment arms (HR 1.01; 95% CI, 0.64-1.59; P ¼ 0.97; Figure 2 ). R0-resection was not reached in 5 of 131 operated patients (4%) in the cetuximab group and in 4 of 128 operated patients (3%) in the control group.
The trend to a better outcome in the cetuximab group was consistent across all subgroups for PFS and more pronounced for OS, reaching statistical significance for higher T-category (T3/4; HR 0.70: 95% CI, 0.49-1.00) and longer length of the primary (>5 cm; HR 0.67: 95% CI, 0.46-0.99) (supplementary Figure. S1 , available at Annals of Oncology online).
The median OS time in the subgroup analysis of squamous cell cancer was in the investigational arm not yet reached and in the control arm 2.5 years in favor of the investigational arm (HR 0.64). The median OS of adenocarcinoma was in the investigational arm 5.1 years and in the control arm 3.2 years in favor of the investigational arm (HR 0.78).
Safety
The frequency and severity of adverse events occurring during either neoadjuvant induction chemotherapy or chemoradiation showed only minor differences (supplementary Table S1 , available at Annals of Oncology online). The addition of cetuximab led to higher rates of hypomagnesemia and allergic reactions.
However, the addition of cetuximab seemed rather to reduce local problems typically caused by radiotherapy, such as the rate of dysphagia (-15%, P ¼ 0.002) and esophagitis (-4%) in this setting.
Overall, 146 (49%) of the randomized patients (n ¼ 300) died during follow-up; 20 deaths (7%) were classified as treatment- There were fewer tumor-related deaths in the cetuximab group compared with the control group (40 versus 54). The number of treatment-related deaths was identical in both groups: 10 patients (7%) each. There were two treatment-related deaths during neoadjuvant treatment: one patient in each group. Overall postoperative mortality was 6% in both groups (supplementary Table S2 , available at Annals of Oncology online).
Discussion
The primary aim of the SAKK 75/08 trial was to improve the outcome of patients with locally advanced, resectable esophageal carcinoma by adding the EGFR inhibitor cetuximab to trimodal therapy. Our results show that the loco-regional relapse rate was significantly reduced by the addition of cetuximab, whereas the distant failure rate was not influenced. Together this resulted in a nonsignificant improvement of PFS, the primary end point, and a more pronounced, almost significant increase in OS. After 4 years' follow-up, the absolute difference amounted to 13% in OS and 11% in PFS.
The clinically meaningful effect of cetuximab on loco-regional relapse may be due to synergism between cetuximab and radiotherapy. Besides a somewhat higher rate of transthoracic resections in the cetuximab arm (79% versus 70%), all other factors that might have influenced local tumor control were well balanced between groups. The effect was seen in both histologies, but was more pronounced in SSC for all end points.
In two phase III trials in metastatic esophago-gastric cancer, EGFR-inhibitors were added to different chemotherapy regimens. In line with our results, investigators were not able to prove a beneficial systemic effect with the addition of cetuximab [6, 7] . In the SCOPE-1 and the RTOG 0436 studies, cetuximab was added to definitive chemoradiation in mainly unresectable, locally advanced esophageal carcinoma of both histologies [8, 9] . In the RTOG trial, OS and clinical complete remission were not improved by cetuximab [9] . The cetuximab arm in the SCOPE-1 trial even showed a significantly shorter median survival, and distinctly less dose of chemoradiation was delivered due to more toxicity in the cetuximab arm [8] .
Our trial was the first to report results of trimodal treatment in patients with resectable tumors. The addition of cetuximab showed a relevant difference in loco-regional failure. In both trials mentioned above, patients with more advanced disease were included; in SCOPE-1 almost 50% of patients had unresectable disease due to local extent of tumors, and in RTOG 0436, stage M1a could be included. If loco-regional control can make an impact on survival, this appears more likely in less advanced disease.
In the subgroup analysis of our trial, most benefit was reached in primary tumors longer than 5 cm in diameter and Tcategory 3, both surrogate markers for tumor load, making these patients at a higher risk of loco-regional, residual microscopic disease after resection. Taking into consideration the result of the French FFCD 9901 trial [10] , where patients with stages I (2) 107 (0) 106 (1) 81 (3) 73 (0) 65 (4) 49 (11) 34 (29) 25 (21) 15 (18) 10 (14) 3 (11) 0 (10) 0 ( 122 (5) 116 (2) 102 (0) 92 (1) 84 (5) 68 (7) 41 (37) 31 (28) 19 (20) 14 (16) 5 (12) 1 (13) 0 ( (1) 53 (4) 47 (4) 26 (22) 21 (19) 14 (11) 10 ( and II achieved no benefit from neoadjuvant chemoradiation, the window of opportunity for intensified chemoradiation with addition of cetuximab may be limited to locally advanced, but still resectable disease. In these patients, loco-regional relapses are frequent and often isolated and have a relevant impact on OS. This is in contrast to more advanced stages where the effect of loco-regional control is diluted by a higher rate of distant metastases.
In this phase III trial, the rate of pathologic complete remission was only slightly higher by adding cetuximab. Since there was no central pathologic review, it may well be that there was some heterogeneity in the kind of assessments performed in more than 50 participating centers. Therefore, the comparison of remission rates between the two treatment groups should be handled with care.
Toxicity due to addition of cetuximab to neoadjuvant treatment was low: patients in the cetuximab group experienced more hypomagnesemia, skin rash, and allergic reactions than controls. Furthermore, there was no significant difference in postoperative morbidity or mortality. It seems that chemotherapy with cisplatin and a taxane is better tolerated in combination with cetuximab and concomitant radiotherapy than cisplatin with 5-FU, as observed in the SCOPE-1 trial [8] .
Our trial has some limitations. (i) We did not reach the planned event rate until the primary analysis making our trial retrospectively underpowered. This was most probably caused by setting an overly ambitious HR as the goal and because fewer events were observed in both arms than estimated in the statistical assumptions. Although the first analysis was delayed, only six additional events have occurred within 1 year and correspondingly a plateau of the survival curves has been reached. (ii) We included both SCC and adenocarcinoma. However, in our subgroup analysis we recorded the same direction of effect in both histologies. The high resection rate of 87% of all patients and R0-resection rate in 96% of all operated patients reflects proper selection of patients, high adherence to the protocol, and the overall quality of the trial. (iii) We did not prospectively test for potential biomarkers of EGFR-inhibition in this patient cohort. RAS mutations are rare in upper GI cancer and a strict correlation between mutation status and EGFR-antibody efficacy like in colorectal cancer cannot be transferred to upper GI tumors. Elevated EGFR gene copy numbers have been described to be associated with better OS in gastric and esophago-gastric cancer patients treated with cetuximab and chemotherapy [11] , and a recent retrospective study showed that patients with EGFR amplification gained greatest benefit from the EGFR-inhibitor gefitinib [12] . A broad scientific program has accompanied this large trial to investigate molecular markers that may serve as surrogate for resistance to EGFR-inhibitors, platinum chemotherapy, or radiation, which will be reported later.
Conclusion
In conclusion, this is the first trial in resectable, locally advanced esophageal cancer showing that addition of the EGFR-inhibitor cetuximab to a multimodal treatment significantly improved loco-regional control, possibly due to synergism between cetuximab and radiotherapy. Better loco-regional control led to statistically not significant improvement of OS with an absolute difference of 13% after 4 years. The effect was seen in both histologies, but was more pronounced in squamous cell cancer in all end points. The addition of neoadjuvant cetuximab did not increase toxicity or postoperative morbidity.
These findings were not practice changing, but clinically relevant for future developments to further improve the outcome in patients with locally advanced, but still resectable disease, particularly with squamous cell histology.
